Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer
To compare invasive disease-free survival (IDFS) of patients with triple-negative breast cancer (TNBC) who have either >= 1 cm residual invasive breast cancer and/or positive lymph nodes (> ypN+) after neoadjuvant chemotherapy randomized to receive 1 year of MK-3475 (pembrolizumab) adjuvant therapy compared to no MK-3475 (pembrolizumab), in both the entire study population and also in the PD-L1 positive subset.
This research study is led by Dr. Grace Makari-Judson.
Contact: Ruth Barham, 413-794-3186
Cancer - Breast,
D’Amour Center for Cancer Care, 3350 Main Street, Springfield, MA
Triple negative breast cancer, post neoadjuvant chemotherapy.
Interventional (Clinical Trial), Randomized